Once-Weekly Semaglutide Shows Promise for Alcohol Use Disorder

A clinical trial suggests semaglutide may reduce alcohol consumption and cravings in adults with alcohol use disorder

Feb 13, 2025

∙ Paid

A professional medical illustration depicting the impact of semaglutide on alcohol use disorder. The image should feature a clean and modern design, showing a symbolic representation of alcohol reduction, such as a fading alcohol bottle or a declining alcohol consumption graph. Include a simplified depiction of the brain, highlighting areas related to cravings and impulse control, with subtle neuron connections representing neurological changes. Use a color palette that conveys positivity and innovation, with blue and green hues for a scientific and clinical feel. Incorporate small medical icons, such as a GLP-1 receptor symbol, to visually tie in the mechanism of action. Ensure the design remains professional, engaging, and easy to understand, avoiding any unsettling or overly complex details.

Topline: A recent phase 2 randomized clinical trial found that low-dose semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), reduced alcohol consumption and cravings in adults with alcohol use disorder (AUD). These findings support further research into GLP-1RA medications as potential treatments for AUD.

Study Details

Alcohol use disorder (…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.